Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study

Cohort study (n=207,817 SGLT2 inhibitor users matched to 207,817 DPP-4 inhibitor users) found no link between SGLT2 inhibitor use and below-knee amputations among patients with type 2 diabetes vs DPP-4 inhibitor use (amputation rate =1.3 & 1.5 per 1000 person-years, respectively)


Diabetes Care